(Reuters) - Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial.
Tresiba, already available outside the United States, was rebuffed by the FDA two years ago on concerns that the drug could be linked to higher rates of heart attacks or strokes.
21:21 Texas saw the most flood victims of any state in 20162
21:06 Apple's Q4 2016 results: Better than expected with 45.5 million iPhones sold, but revenue continues to slide13
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger13
12:23 Lockheed Martin's quarterly profit handily beats estimates13